Centre for Evidence-Based Medicine Odense (CEBMO), Odense University Hospital, Odense, Denmark.
Nordic Cochrane Centre, Rigshospitalet, Copenhagen, Denmark.
Cochrane Database Syst Rev. 2020 Dec 8;12(12):MR000040. doi: 10.1002/14651858.MR000040.pub3.
Treatment and diagnostic recommendations are often made in clinical guidelines, reports from advisory committee meetings, opinion pieces such as editorials, and narrative reviews. Quite often, the authors or members of advisory committees have industry ties or particular specialty interests which may impact on which interventions are recommended. Similarly, clinical guidelines and narrative reviews may be funded by industry sources resulting in conflicts of interest.
To investigate to what degree financial and non-financial conflicts of interest are associated with favourable recommendations in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews.
We searched PubMed, Embase, and the Cochrane Methodology Register for studies published up to February 2020. We also searched reference lists of included studies, Web of Science for studies citing the included studies, and grey literature sources.
We included studies comparing the association between conflicts of interest and favourable recommendations of drugs or devices (e.g. recommending a particular drug) in clinical guidelines, advisory committee reports, opinion pieces, or narrative reviews.
Two review authors independently included studies, extracted data, and assessed risk of bias. When a meta-analysis was considered meaningful to synthesise our findings, we used random-effects models to estimate risk ratios (RRs) with 95% confidence intervals (CIs), with RR > 1 indicating that documents (e.g. clinical guidelines) with conflicts of interest more often had favourable recommendations. We analysed associations for financial and non-financial conflicts of interest separately, and analysed the four types of documents both separately (pre-planned analyses) and combined (post hoc analysis).
We included 21 studies analysing 106 clinical guidelines, 1809 advisory committee reports, 340 opinion pieces, and 497 narrative reviews. We received unpublished data from 11 studies; eight full data sets and three summary data sets. Fifteen studies had a risk of confounding, as they compared documents that may differ in other aspects than conflicts of interest (e.g. documents on different drugs used for different populations). The associations between financial conflicts of interest and favourable recommendations were: clinical guidelines, RR: 1.26, 95% CI: 0.93 to 1.69 (four studies of 86 clinical guidelines); advisory committee reports, RR: 1.20, 95% CI: 0.99 to 1.45 (four studies of 629 advisory committee reports); opinion pieces, RR: 2.62, 95% CI: 0.91 to 7.55 (four studies of 284 opinion pieces); and narrative reviews, RR: 1.20, 95% CI: 0.97 to 1.49 (four studies of 457 narrative reviews). An analysis combining all four document types supported these findings (RR: 1.26, 95% CI: 1.09 to 1.44). One study investigating specialty interests found that the association between including radiologist guideline authors and recommending routine breast cancer screening was RR: 2.10, 95% CI: 0.92 to 4.77 (12 clinical guidelines).
AUTHORS' CONCLUSIONS: We interpret our findings to indicate that financial conflicts of interest are associated with favourable recommendations of drugs and devices in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews. However, we also stress risk of confounding in the included studies and the statistical imprecision of individual analyses of each document type. It is not certain whether non-financial conflicts of interest impact on recommendations.
治疗和诊断建议通常在临床指南、顾问委员会会议报告、社论等意见文章以及叙述性评论中提出。作者或顾问委员会成员通常与行业有联系,或有特殊的专业利益,这可能会影响推荐的干预措施。同样,临床指南和叙述性评论可能由行业来源资助,从而产生利益冲突。
调查财务和非财务利益冲突与临床指南、顾问委员会报告、意见文章和叙述性评论中的有利建议之间的关联程度。
我们检索了截至 2020 年 2 月发表的 PubMed、Embase 和 Cochrane 方法学登记处的研究。我们还检索了纳入研究的参考文献列表、引用纳入研究的 Web of Science 以及灰色文献来源。
我们纳入了比较利益冲突与药物或设备(例如推荐特定药物)的临床指南、顾问委员会报告、意见文章或叙述性评论中有利建议之间关联的研究。
两名综述作者独立纳入研究、提取数据并评估偏倚风险。当认为荟萃分析有助于综合我们的发现时,我们使用随机效应模型估计风险比(RR)及其 95%置信区间(CI),RR>1 表示存在利益冲突的文件(例如临床指南)更常具有有利的建议。我们分别分析了财务和非财务利益冲突的关联,并对四种类型的文件分别进行了分析(预先计划的分析)和组合分析(事后分析)。
我们纳入了 21 项研究,分析了 106 项临床指南、1809 份顾问委员会报告、340 份意见文章和 497 份叙述性评论。我们从 11 项研究中收到了未发表的数据;其中 8 个完整数据集和 3 个汇总数据集。15 项研究存在混杂风险,因为它们比较的文件在利益冲突以外的方面可能存在差异(例如,用于不同人群的不同药物的文件)。财务利益冲突与有利建议之间的关联为:临床指南,RR:1.26,95%CI:0.93 至 1.69(8 项研究中的 86 项临床指南);顾问委员会报告,RR:1.20,95%CI:0.99 至 1.45(4 项研究中的 629 份顾问委员会报告);意见文章,RR:2.62,95%CI:0.91 至 7.55(4 项研究中的 284 份意见文章);叙述性评论,RR:1.20,95%CI:0.97 至 1.49(4 项研究中的 457 份叙述性评论)。合并所有四种文件类型的分析支持了这些发现(RR:1.26,95%CI:1.09 至 1.44)。一项研究调查了专业利益,发现包括放射科指南作者与推荐常规乳腺癌筛查之间的关联,RR:2.10,95%CI:0.92 至 4.77(12 项临床指南)。
我们认为,财务利益冲突与临床指南、顾问委员会报告、意见文章和叙述性评论中药物和设备的有利建议有关。然而,我们也强调了纳入研究中的混杂风险以及对每种文件类型的单独分析的统计不精确性。非财务利益冲突是否会影响建议尚不确定。